All News

The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).

Patients with MPNs who are JAK2V617F- and CALR-positive had different bacterial compositions compared with people without MPNs, research found.

Here is what I would say to King Charles III after his recent cancer diagnosis.

The novel drug BMX-001 showed improved survival in certain patients with high-grade glioma and reduced cognitive decline caused by radiation therapy.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

After cancer, I finally went on a cruise and allowed myself to fight through my fears, which felt so freeing.

Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.

Anktiva boosted responses to BCG treatment without affecting quality of life, research showed.

At a cancer support group at my church, we sit together and share our cancer stories.

I've been living with small lymphocytic lymphoma for 14 years now, but it has taught be some valuable lessons about life.

A 2.5-mg dose of olanzapine provided similar control of nausea/vomiting as the standard 10-milligram dose in patients with solid tumors receiving chemotherapy.

A digital tool for caregivers of patients with cancer in hospice care significantly reduced some of the caregiver burden while improving their mood.

New guidelines provide a framework for pediatric neuroblastoma treatment — as well as conversations families should have with their oncology teams.

I lived by Nike's motto, "Just do it!" and worked to gain my muscle back after cancer.

From the San Francisco 49ers’ Trent Williams looking back on his cancer experience to a Republican congressman returning to work after myeloma treatment, here’s what’s happening in the oncology space this week.

Patients with relapsed or refractory multiple myeloma had lower progressive disease outcomes when receiving Blenrep with Velcade and dexamethasone, research found.

Treatment for muscle-invasive bladder cancer called dose-dense MVAC did not improve survival compared with chemotherapy alone, although one drug in the combination faces a shortage.

An expert said that he is optimistic about the future use of biomarkers in the kidney cancer space.

The anxiety of cancer will seemingly never go away.

Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.

The Food and Drug Administration granted a priority review to Blincyto for the treatment of early-stage CD19-positive B-cell acute lymphoblastic leukemia.

Substance use disorders, such as alcohol use disorder, were found to be more prevalent among survivors of specific cancer types, according to research.

Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when compared with those treated with Imfinzi or subject to observation.

I felt like I had to come back to life after hearing the word “metastatic.”

The Food and Drug Administration granted a Fast Track designation to the novel drug, ARV-471 for patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer.

The development of immune-related side effects is associated with improved overall survival among patients with metastatic non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitor therapy.

As a survivor, Karen Gartland found that a mind-body program was helpful, as it taught her useful techniques for when her health anxiety spikes.

“We have to make it known to people that we are not just a patient,” said Michelle Anderson-Benjamin, CEO of the Fearless Warrior Project, who received a diagnosis of metastatic breast cancer in 2022.